EUVIMEDEUVIMED entdecken
Crossref

Pharmacological characteristics and clinical study results of the first RAS inhibitor sotorasib (LUMAKRAS®) for non-small cell lung cancer with KRAS G12C mutation

Hirotoshi Hoshiyama

Folia Pharmacologica Japonica · 2023

DOI: 10.1254/fpj.22148 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Folia Pharmacologica Japonica, 2023. Verfasst von Hirotoshi Hoshiyama. Beteiligte Einrichtung: Amgen K.K. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsAntineoplastic AgentsAnimalsMiceHumansProto-Oncogene Proteins p21(ras)MutationGuanosine TriphosphatePiperazinesPyridinesPyrimidines

Substanzen

Proto-Oncogene Proteins p21(ras)Antineoplastic AgentsGuanosine TriphosphatesotorasibPiperazinesPyridinesPyrimidinesKRAS protein, human

Autor:innen und Institutionen

  • Amgen K.K.

Zitieren

APA

Hoshiyama, H. (2023). Pharmacological characteristics and clinical study results of the first RAS inhibitor sotorasib (LUMAKRAS®) for non-small cell lung cancer with KRAS G12C mutation. Folia Pharmacologica Japonica. https://doi.org/10.1254/fpj.22148

Vancouver

Hoshiyama H. Pharmacological characteristics and clinical study results of the first RAS inhibitor sotorasib (LUMAKRAS®) for non-small cell lung cancer with KRAS G12C mutation. Folia Pharmacologica Japonica. 2023. doi:10.1254/fpj.22148

BibTeX
@article{Hoshiyama2023,
  author = {Hoshiyama, Hirotoshi},
  title = {Pharmacological characteristics and clinical study results of the first RAS inhibitor sotorasib (LUMAKRAS®) for non-small cell lung cancer with KRAS G12C mutation},
  journal = {Folia Pharmacologica Japonica},
  year = {2023},
  doi = {10.1254/fpj.22148}
}
Kostenlos starten →